• Active Substance: Glasdegib
  • Name: Daurismo
  • Therapeutic area: Acute myeloid leukaemia (AML)
  • Pharmaceutical company: Pfizer Pharma GmbH


Time table:

  • Publication of project plan: 06.05.2020
  • Publication of final assessment: 30.07.2020


Assessment information:

G-BA assessment not available
Reason: Start of the assessment was 15.08.2020. The final decision is expected in the middle of February 2021.

  • Title: Glasdegib indicated for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML)
  • Author/Co-Author: DVSV (Austria), NCPE (Ireland)
  • Dedicated Reviewers: INFARMED (Portugal), SNHTA (Switzerland), HAS (France)